leadf
logo-loader
viewCanafarma

CanaFarma Hemp Products developing bioequivalent drug to Hydroxychloroquine with partner PharmOps

Canafarma Hemp Products Corp (CSE:CNFA) COO Frank Barone tells Proactive the firm is teaming up with private drugs group PharmOps to develop a bioequivalent drug to Hydroxychloroquine amid the coronavirus pandemic.

Barone says while there are controversies surrounding Hydroxychloroquine's effectiveness in the fight against coronavirus, he says there is a 'sizable demand' for the product.

Quick facts: Canafarma

Price: 0.435 CAD

CSE:CNFA
Market: CSE
Market Cap: $81.48 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Canafarma named herein, including the promotion by the Company of Canafarma in any Content on the Site, the Company receives from said issuer...

FOR OUR FULL DISCLAIMER CLICK HERE

Canafarma Hemp partners with Dutch pharma company to develop hemp-based time...

CanaFarma Hemp Products Corp. (CSE:CNFA) COO Frank Barone tells Proactive the group has partnered with Dutch pharmaceutical company APeT BV to develop hemp-based cannabinoid, drug and nutritional supplement delivery methods using its FLOTEX‐C patented technology. Barone says FLOTEX‐C ensures...

on 16/9/20

2 min read